COVID-19 Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Cost–Benefit Analysis

Nurchis, Mario Cesare; Lontano, Alberto; Pascucci, Domenico; Sapienza, Martina; Marziali, Eleonora; Castrini, Francesco; Messina, Rosaria; Regazzi, Luca; Causio, Francesco Andrea; Pilla, Andrea Di; Vetrugno, Giuseppe; Damiani, Gianfranco; Laurenti, Patrizia

doi:10.3390/ijerph19137848

Cited by 5 publications

(14 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The basic and vaccination characteristics of the included studies are presented in Table 1. Of the 28 included studies, 13 were from highincome countries (HICs): America (n = 7), [9][10][11][12][13][14][15] Italy (n = 2), 16,17 Canada (n = 1), 18 Denmark (n = 1), 19 the United Kingdom (n = 1), 20 and Spain (n = 1). 21 The remaining studies were from less developed countries, specifically, China (n = 3), [22][23][24] Brazil (n = 2), 25,26 Turkey (n = 1), 27 Iran (n = 1), 28 Pakistan (n = 1), 29 Colombia (n = 1), 30 South Africa (n = 1), 31 Thailand (n = 1), 32 Ukraine (n = 1), 33 Poland (n = 1), 34 Kenya (n = 1), 35 and multiple countries/regions (n = 1).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…36 For the publication years, 15 studies were published in 2021, [11][12][13][14][15][16][18][19][20]22,27,29,[31][32][33] and 13 were published in the first half of 2022. 9,10,17,21,[23][24][25][26]28,30,[34][35][36] Regarding the study perspective, 12 studies were from the health system perspective, 10,12,[16][17][18][19]23,25,26,30,31,33 10 were from the societal or payer perspective, 9,13,15,16,20,24,28,[34][35][36] ...…”

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Cost‐effectiveness of COVID‐19 vaccination: A systematic review

Zhao

Han

et al. 2023

J Evidence Based Medicine

View full text Add to dashboard Cite

Objective The COVID‐19 vaccination strategy has been widely used to protect population health worldwide. This study aims to summarize the cost‐effectiveness evidence of economic evaluation of COVID‐19 vaccination strategies to provide evidence supporting the usage of COVID‐19 vaccination, especially where the supply of COVID‐19 vaccine is limited. Methods A systematic literature review was performed by searching both English and Chinese databases, including PubMed, Embase, Science Direct, Web of Science, Medline, Scopus, and CNKI. Articles published from January 1, 2020 to August 1, 2022 (PROSPERO registration number: CRD42022355442). Results Of the 1035 papers identified, a total of 28 English studies that met the preset criteria were included. COVID‐19 vaccination and booster vaccination were cost‐effective or cost‐saving regardless of the vaccine type; vaccine efficacy, vaccine price, vaccine supply or prioritization, and vaccination pace were the influential factors of cost‐effectiveness among different population groups. When supply is adequate, mass vaccination should be encouraged, while when supply is inadequate, prioritizing the high risk and the elderly is more cost‐effective. Conclusions COVID‐19 vaccination strategies are economically favorable in a wide range of countries and population groups, and further research on suitable strategies for booster COVID‐19 vaccination is needed.

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Cost‐effectiveness of COVID‐19 vaccination: A systematic review

Zhao

Han

et al. 2023

J Evidence Based Medicine

View full text Add to dashboard Cite

show abstract

“…A previous study of 6649 HCWs in our teaching hospital reported an efficacy of the primary schedule of BNT162b2 against SARS-CoV-2 infection of 91.5% [ 11 ]. Moreover, evidence in the scientific literature shows that providing the Pfizer–BioNTech BNT162b2 mRNA vaccine to HCWs results in significant economic benefits [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Risk of Infection and Duration of Protection after the Booster Dose of the Anti-SARS-CoV-2 Vaccine BNT162b2 among Healthcare Workers in a Large Teaching Hospital in Italy: Results of an Observational Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

The efficacy of the first schedule of COVID-19 mRNA vaccines has decreased after the surge of the Delta variant, posing the need to administer a booster dose to enhance the neutralising immune response. This study aims at evaluating the duration of protection given by the booster dose of Pfizer–BioNTech BNT162b2 mRNA vaccine in healthcare workers (HCWs) of a large teaching hospital in Rome and to analyse the factors associated with post-booster vaccination infections. Data about vaccinations of HCWs with the BNT162b2 vaccine and nasal swabs positive for SARS-CoV-2 were extracted from the digital archives of the hospital from 27 September 2021 to 31 May 2022. In total, 5770 HCWs were observed. The cumulative risk of becoming infected by SARS-CoV-2 increased with time (2.5% at 4 weeks, 17% at 12 weeks and 40% at 24 weeks) and was significantly higher for females, younger classes of patients and for those who had developed a hybrid immunity (natural infection plus one dose, namely the primary schedule, added to the booster dose) compared to those who had completed the three doses. This study describes the duration and the determinants of the protection against infections after the booster dose of COVID-19 vaccine, highlighting the need for continuous monitoring of vaccine-induced immunogenicity.

show abstract

“…However, the cost-effectiveness of vaccination strategies depends on the vaccine type (Orangi et al 2022;Wang et al 2022) and the booster policy (Mungmunpuntipantip and Wiwanitkit 2022). Given the vaccine's reduced potency and the virus strain variation (Nurchis et al 2022), the economic evaluation of the Covid-19 vaccine needs further analysis for a longer time (Fu et al 2022a).…”

Section: Literature Resultsmentioning

confidence: 99%

Economic Evaluation of Covid-19 Vaccines: A Literature Review

Liu¹

2023

HBEM

View full text Add to dashboard Cite

The Covid-19 epidemic and virus variants affect public health security worldwide continuously. Conducting Covid-19 vaccination economic evaluation by measuring the cost and outcomes helps governments or healthcare departments choose a better policy or adjust the vaccination policy periodically. We systematically reviewed the health economic evaluation studies on different immunization policies of vaccines in Covid-19. It is found that the existing studies still need to be improved. For model design, studies lack compelling predictions of dynamic transmission between epidemiological regions; for parameters, researchers reduce the selection of related indexes in cost calculation to simplify the model; for data collection, some research needs real-world data support. Therefore, comparative research should be conducted more dynamically and sustainably by improving the evaluation's quality and promoting standards and conclusions to strengthen the guiding role of vaccination economic evaluation in policy selection.

show abstract

COVID-19 Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Cost–Benefit Analysis

Cited by 5 publications

References 43 publications

Cost‐effectiveness of COVID‐19 vaccination: A systematic review

Cost‐effectiveness of COVID‐19 vaccination: A systematic review

Risk of Infection and Duration of Protection after the Booster Dose of the Anti-SARS-CoV-2 Vaccine BNT162b2 among Healthcare Workers in a Large Teaching Hospital in Italy: Results of an Observational Study

Economic Evaluation of Covid-19 Vaccines: A Literature Review

Contact Info

Product

Resources

About